Mark Litton : Appointed President and CEO : Alpine Immune Sciences
Alumnus Mark Litton MBA ‘94 was appointed to President and CEO of Alpine Immune Sciences to strengthen the leadership team. Alpine Immune Sciences, Inc. is a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases. Mark Litton joins Alpine from Alder BioPharmaceuticals. He co-founded the company in 2004 and served as the Chief Business Officer and Treasurer.
“Mark’s deep experience in operating and growing life science companies, as well as developing strategy and executing transactions, will prove invaluable as we enter the clinic and the next phase of development as a company,” said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine, in a recent press release. “We believe we are on the cusp of an exciting potential breakthrough in the next generation of therapies for cancers and autoimmune/inflammatory diseases, and we are committed to providing better treatment options for patients.”